

# Algorithm to choose between one versus two stents in bifurcation lesion

Bernard Chevalier, MD, FESC, FACC, FSCAI ICPS Massy France



In the last five years , I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Biotronik, Colibri, Cordis, Daichi-Sankyo, Eli-Lilly, Medtronic, Terumo. I am currently minor shareholder & general director of CERC (CRO)

### Potential benefits of SB treatment


• Avoid peri-procedural occlusion  $\rightarrow$  NonQ MI


• Relief of angina

• Keep access for future interventions


### Can we predict occlusion ?

- Two mechanisms
  - Spiky carena shift (De Lezo Eurointervention 2012)
  - Longitudinal plaque shift from proximal main vessel (Xu Circ CVI 2013)





### Can we predict angina relief?



#### The angio cut-off value for (jailed) side branches is 75% DS

- DS<75%: high NPV
- Reason: radiographic artefact (white halo)
  - small branches, small myocardial mass, low flow
- Most likely idem with non-jailed SB
- Oedema ? Like at day one after IMA implantations

#### Bon-Kwon Koo et al JACC 2005


### Is second stent the solution?

### Safety

A sudy ID Cardiac	death OR (95% CI)	% Weight	B study	Stent thrombosis	OR (95% CI)	% Weight
Pan et al (2004) 🗧 🛞	0.31 (0.01, 7.69)	15.76	Pan et al (2004)		0.31 (0.01, 7.69)	8.35
BBC ONE (2010)	0.60 (0.04, 5.63)	20.47	BBC ONE (2010)		0.20 (0.02, 1.70)	27.14
Colombo et al (2004)	0.93 (0.04, 23.56)	7.97	CACTUS (2009)		0.68 (0.11, 4.11)	15.98
Lin et al (2010)	* 3.06 (0.12, 76.70)	5.00	Colombo et al (2004)		1.45 (0.13, 16.65)	6.39
DKCRUSH-II (2011)	1.00 (0.14, 7,18)	20.33	Lin et al (2010)		3.06 (0.12, 76.70)	2.65
BBK (2008)	2.02 (0.18, 22.64)	10.07	DKCRUSH-II (2011)		0.25 (0.03, 2.22)	21.68
Nordic (2006)	1.00 (0.14, 7.13)	20.40	B8K (2008) -		0.50 (0.04, 5.55)	10.79
CACTUS (2009)	(Excluded)	0.00	Nordie (2006)		3.00 (0.12, 74.07)	2.71
Nordie-Ballic IV (2013)	(Excluded)	0.00	Nordic-Baltic IV (2013)		- 2.07 (0.19, 23.03)	5.32
Overall (I-squared=0.0%, (0=0.950)	0.99 (0.40, 2.41)	100.00	Overall (I-squared=0.0%, p=0.729)	$\diamond$	0.64 (0.31, 1.34)	100.00
Favours simple strategy C Study Early myocard	Favours complex strategy	% Weight	Favours sim D Study 10	ole strategy Favours co	or (95% Ci)	% Weigh
Pan et al (2004)	1.91 (0.17, 21.85)	1.44	Pan et al (2004)		4.89 (0.23, 104.75)	
BBC ONE (2010)	0.28 (0.10, 0.72)	25.85	BBC ONE (2010)		0.30 (0.14, 0.64)	32.86
	Ab 196 - 68		CACTUS (2009)		0.79 (0.39, 1.61)	20.89
CACTUS (2009)	- 0.78 (0.37, 1.62)	23.73	Colombo et al (2004)	<u></u>	0.85 (0.25, 2.96)	6.70
Colombo et al (2004)	0.95 (0.18. 5.09)	4.10	Lin et al (2010)		3.06 (0.12, 76.70)	0.59
.h etal (2010)	1.00 (0.05, 16,41)	1,42	DKCRUSH-II (2011)		0.66 (0.18, 2.38)	7.15
DKCRUSH-II (2011)	0.66 (0.16, 2.38)	8.52	B8K (2008) -		0.50 (0.04, 5.55)	2.41
3BK (2008) 🤆 👘	0.50 (0.04, 5.55)	2.87	Nordic (2006)		0.49 (0.24, 1.01)	26.44
Nordic (2006)	0.40 (0.19, 0.85)	32.27	Nordic-Baltic IV (2013)		2.08 (0.38, 11.49)	2.35
Overall (I-squared=0.0%, p=0.624)	0.53 (0.36, 0.79)	100.00	Overali (I-squared=13.6%, p=0.321)	$\diamond$	0.60 (0.43, 0.66)	100.00
0.0442 1 Favours simple strategy	l 22.6 Favours complex strategy		0.00955 Favours sim	1 be strategy Favours co	l 105 malex strategy	1002512-1


#### Gao et al. Eurointervention 2014

### Efficacy



#### Gao et al. Eurointervention 2014

### Nordic IV: 1,1,1 with SB > 2.75 mm



#### Kumsars et al. TCT 2013

### Some answer @ EuroPCR 2015?

### EBC II trial




Location: Room 252A Session type: Hot line Topic: PCI

13:47-13:54 • A European bifurcation coronary study: a randomised comparison of provisional T-stenting versus a systematic 2-stent strategy in large calibre true bifurcations *D. Hildick-Smith* 

### **Bifurcation lesion analysis**

### Structure-function scaling laws of vascular trees




$$D_{\text{mother}}^{3} = D_{\text{daughter 1}}^{3} + D_{\text{daughter 2}}^{3} + \cdots$$

#### Murray's law

$$D_{\text{mother}} = 0.67^* (D_{\text{daughter 1}} + D_{\text{daughter 2}} + \dots)$$


Finet et al. Eurointervention 2007; 490-8

### Side Branch Lesion is Short



<sup>1</sup> Gobeil et al, Am J Cardiol 2001, <sup>2</sup> Lefèvre et al, Am J Cardiol 2003 (abst. supp.)
<sup>3</sup> Colombo et al, Circulation 2004; 109: 1244-9, Sengotuvel et al, JACC 2004 (abst.supp.)

### Lumen vs Plaque



www.icps.com.fr

Courtesy of R Virmani

### Practical key points

- Pre-intervention assessment:
  - Diameters
  - Angle
  - Plaque distribution (taking into account limitations of 2D angio imaging)
  - Decide which one is the distal side branch
- Mandatory to include these parameters as well as the global context of the patient in strategy making process


### Strengths of Provisional Approach

More simple

### Appropriate technique provide good results

### Minimise caging (better rheology)

### Provisional SB stenting ICPS (2009 vs 2005) 2-years Outcome




Mylotte et al. JACC Interv 2012

### Key points for one stent


• No SB predil

• POT

### **Proximal Optimisation Technique**



*Kissing balloon post dilatation* + *POT (Kaname<sup>R</sup>)* 



### **NC Balloon**

Sized to proximal reference (1:1) Distal marker at carena level.


### Key points for one stent

• No SB predil

• POT


• Distal cell recrossing

3D-OFDI with Stent enhancement enable us to verify recrossing wire position.



#### **Abbreviation**

- MV: Main Vessel
- SB: Side Branch
- GW: Guidewire
- L: Link between cell




OFDI image from Internal bench test.

#### Courtesy of Terumo

# Recrossing wire through distal cell.


# Recrossing wire through proximal cell.



OFDI image from Internal bench test.


# Recrossing wire through distal cell.

# Recrossing wire through proximal cell.



# Recrossing wire through distal cell.


### Recrossing wire through




# Elution from MB to SB

#### Strut Position, Blood Flow, and Drug Deposition Implications for Single and Overlapping Drug-Eluting Stents

Brinda Balakrishnan, SB\*; Abraham R. Tzafriri, PhD\*; Philip Seifert, MS; Adam Groothuis, MS; Campbell Rogers, MD; Elazer R. Edelman, MD, PhD






# Key points


• No SB predil

• POT

• Distal cell recrossing

Modern KBT





# **EU** Guidelines

has not yet been established. Variables to be considered are plaque distribution, size and downstream territory of each vessel (main and side branch), and the bifurcation angle. Stent implantation in the main vessel only, followed by provisional angioplasty with or without stenting of the side branch, seems preferable compared with routine stenting of both vessels. FFR data from side

### US guidelines : bifurcation

#### CLASS I


 Provisional side-branch stenting should be the initial approach in patients with bifurcation lesions when the side branch is not large and has only mild or moderate focal disease at the ostium (726–729). (Level of Evidence: A)

#### **CLASS IIa**

 It is reasonable to use elective double stenting in patients with complex bifurcation morphology involving a large side branch where the risk of side-branch occlusion is high and the likelihood of

successful side-branch reaccess is low (730-733). (Level of Evidence: B)

# When to start with 2 stent technique ?




www.icps.com.fr

Louvard CCI


#### Never


#### **Combination of 3 criteria**


- XX1 Medina
- SB lesion length > 5 mm
- SB supplying a significant myocardium area with a diameter compatible for stenting (>2.25 mm)
- And when SB stenting could be difficult if not done firstfront
- Or when SB identification
   is unclear



















www.icps.com.fr




Louvard CCI


# T or TAP ? (stent boost)




т




TAP

















# Take home message

2 stent technique may be selected based on disease extension in large SB (>2.5 mm, >50%, >5 mm long)

Even in this situation, it is still possible to stent across first in majority of cases

A good one stent technique allows you to avoid two stents in 90% of cases